Abstract
Estrogen signaling has emerged as a pivotal regulator in the development and progression of various cancers, including those of the urological system. While urological malignancies have traditionally been linked with androgen signaling, recent studies reveal a complex interplay where estrogen receptors-ERα, ERβ, and GPER-modulate critical cellular processes such as proliferation, apoptosis, and metastasis in these cancers. Here we show that estrogen receptors, through both genomic and non-genomic pathways, exert dual roles in either promoting or inhibiting tumor growth, making them both a challenge and a potential therapeutic target. These insights suggest that targeting estrogen receptor pathways could offer novel treatment strategies, especially for advanced or therapy-resistant urological tumors.Furthermore, understanding the molecular mechanisms through which estrogen receptors influence tumor progression could lead to the development of more specific and less toxic treatment options. The findings not only shift the paradigm of estrogen's role in cancer biology but also underscore the potential for personalized treatments, where estrogen receptor status could be used to tailor more effective and individualized therapeutic regimens. This review ushers in new possibilities for advancing urological oncology, where estrogen signaling may hold the key to overcoming current therapeutic challenges and improving clinical outcomes.